LIPO (lipella.com) Market Value to Book Value Ratio
The development of bladder therapy methods promises Lipella Pharmaceuticals (LIPO) stable demand for its drugs. The price-to-book history visualizes this potential, with the current level standing at 0.53. Innovations in the local delivery of liposomal anti-inflammatory agents form the business foundation, while experienced batches of test solutions are produced through reliable contract partners.
%3A%20Market%20Capitalization%20to%20Net%20Assets&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_LIPO_-_Lipella-Pharmaceuticals_-_Market-Capitalization-to-Net-Assets "LIPO Lipella Pharma Market Capitalization to Book Value Ratio (04/28/2023 - 07/19/2025) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Lipella Pharmaceuticals Inc (LIPO)
This ratio reflects the relationship between the market value of the business and the value of its net assets. By analyzing the history of the market-to-book value multiple, an investor assesses the premium for control over assets. The calculation is based on dividing the market valuation by the book capital. For Lipella Pharmaceuticals (LIPO), this indicator shows the degree of asset undervaluation relative to the prospects of the LP-10 drug. Low values here may mask risks, despite the potential in cancer treatment.